MaxCyte, Inc. (MXCT): Cost of Revenue
$6.22M
Year ended 2025-12-31
$6.45M
Trailing 12 months to 2026-06-30
+6.9%
3-year compound annual growth
+17.6%
5-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $6.22M | -12.4% | 2026-03-25, From 2025-01-01 |
| 2024-12-31 | $7.10M | +49.7% | 2026-03-25, From 2024-01-01 |
| 2023-12-31 | $4.74M | -7.0% | 2025-03-11, From 2023-01-01 |
| 2022-12-31 | $5.10M | +39.8% | 2024-03-12, From 2022-01-01 |
| 2021-12-31 | $3.65M | +31.8% | 2023-03-15, From 2021-01-01 |
| 2020-12-31 | $2.77M | +10.7% | 2022-03-22, From 2020-01-01 |
| 2019-12-31 | $2.50M | n/a | 2022-03-22, From 2019-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| MaxCyte, Inc. (MXCT) | 2025-12-31 | $6.22M | -12.4% |
| iSpecimen Inc. (ISPC) | 2025-12-31 | $1.90M | -64.1% |
| OneMedNet Corp (ONMD) | 2025-12-31 | $1.86M | +101.5% |
| Cannabis Bioscience International Holdings, Inc. (CBIH) | 2025-05-31 | $40.1K | -12.0% |
| Incyte Corp (INCY) | 2025-12-31 | $372.13M | +19.2% |
| Icon PLC (ICLR) | 2024-12-31 | $5.85B | +2.2% |
| Weed, Inc. (BUDZ) | 2025-12-31 | $0 | n/a |
| Vitaspring Biomedical Co. Ltd. (VSBC) | 2026-01-31 | $0 | n/a |
Compare MXCT, ISPC, ONMD, CBIH side by side · Screen every company in Services-Commercial Physical & Biological Research ↗